-
Start Preamble
By Notice dated December 24, 2003, and published in the Federal Register on January 27, 2004, (69 FR 3946), Noramco, Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Amphetamine (1100) II Oxycodone (9143) II Hydrocodone (9193) II Morphine (9300) II Thebaine (9333) II Sufentanil (9740) II Fentanyl (9801) II The firm plans to support its other manufacturing facility with manufacturing and analytical testing.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Noramco, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.
Start SignatureDated: April 28, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-10798 Filed 5-11-04; 8:45 am]
BILLING CODE 4410-09-M
Document Information
- Published:
- 05/12/2004
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- 04-10798
- Pages:
- 26408-26408 (1 pages)
- PDF File:
- 04-10798.pdf